Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 06835375

Next Previous
Search
Drug Profile

PF 06835375

Alternative Names: PF-06835375

Latest Information Update: 10 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action CXCR5 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura
  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 03 Jun 2023 PF 06835375 is still in phase I trials for Systemic-lupus-erythematosus and Rheumatoid-arthritis in USA (NCT03334851)
  • 03 Jun 2023 Safety and pharmacokinetics data from a phase I trial in Systemic lupus erythematosus and Rheumatoid arthritis were presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023) .
  • 18 Apr 2023 Pfizer re-initiates a phase II trial in Idiopathic thrombocytopenic purpura (In adults, In the elderly) in Canada, Czech Republic, Czech Republic, Australia, Poland, Hungary and USA (SC) (NCT05070845)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top